Trelegy ellipta and Thinking abnormal - a phase IV clinical study of FDA data

Summary:

Thinking abnormal is reported as a side effect among people who take Trelegy ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate), especially for people who are male, 60+ old, also take Lamictal, and have Chronic obstructive pulmonary disease.

The phase IV clinical study analyzes which people have Thinking abnormal when taking Trelegy ellipta. It is created by eHealthMe based on reports of 27,966 people who have side effects when taking Trelegy ellipta from the FDA, and is updated regularly.

What is Trelegy ellipta?

Trelegy ellipta has active ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 28,101 Trelegy ellipta users. Check the latest studies of Trelegy ellipta.

What is Thinking abnormal?

Thinking abnormal is found to be associated with 1,060 drugs and 1,185 conditions by eHealthMe. Check the latest studies of Thinking abnormal.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

27,966 people reported to have side effects when taking Trelegy ellipta.
Among them, 12 people (0.04%) have Thinking abnormal.

Could Trelegy ellipta cause Thinking abnormal?

Among these 12 people:

What is the gender of people who have Thinking abnormal when taking Trelegy ellipta? *

female: 45.45 %
male: 54.55 %

What is the age of people who have Thinking abnormal when taking Trelegy ellipta? *

What are other drugs people take besides Trelegy ellipta? *

What are other side effects people have besides Thinking abnormal? *

Mental Disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability): 3 people, 25.00%
Memory Loss: 3 people, 25.00%
Feeling Abnormal: 3 people, 25.00%
Mental Impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition): 2 people, 16.67%
Tremor (trembling or shaking movements in one or more parts of your body): 2 people, 16.67%
Hypokalemia (low potassium): 2 people, 16.67%
Fatigue (feeling of tiredness): 2 people, 16.67%
Fall: 2 people, 16.67%
Dyspnea (difficult or laboured breathing): 2 people, 16.67%
Drug Hypersensitivity: 2 people, 16.67%

What are the existing conditions these people have? *

Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 25.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 16.67%
Dyskinesia (abnormality or impairment of voluntary movement): 1 person, 8.33%
Asthma: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Trelegy ellipta and have Thinking abnormal?

- Check whether Thinking abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Trelegy ellipta:

Trelegy ellipta (28,101 reports)

Thinking abnormal treatments and more:

Thinking abnormal (22,435 reports)

How severe was Thinking abnormal and when was it recovered:

Thinking abnormal in Trelegy ellipta

Expand to all the drugs that have ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate:

Thinking abnormal and drugs with ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Trelegy ellipta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thinking abnormal:

Thinking abnormal (1,060 drugs)

Browse all the conditions that are associated with Thinking abnormal:

Thinking abnormal (1,185 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fluticasone furoate; umeclidinium bromide; vilanterol trifenatate (the active ingredients of Trelegy ellipta) and Trelegy ellipta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.